Pomerantz LLP Investigates Potential Securities Claims Against Pliant Therapeutics, Inc.
NEW YORK, Feb. 25, 2025 – Pomerantz LLP, a leading securities law firm, is investigating potential securities claims on behalf of investors of Pliant Therapeutics, Inc. (“Pliant” or the “Company”) (NASDAQ: PLRX).
Background
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for the treatment of fibrotic diseases. The Company’s lead product candidate, PLN-74801, is a selective and potent FGF21 receptor agonist being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.
The Investigation
The investigation concerns whether Pliant and certain of its officers and directors have made false and/or misleading statements and/or failed to disclose material information in violation of the Securities Exchange Act of 1934 (the “Exchange Act”).
Allegations
Specifically, the investigation focuses on certain statements made by the Company regarding the development and commercial potential of PLN-74801. The investigation is based on publicly available information and it is still in its early stages.
Impact on Individual Investors
If you are an investor in Pliant Therapeutics and have suffered a loss, you may be entitled to recover your damages. The investigation is ongoing, and Pomerantz LLP encourages investors to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 167 to discuss the legal options available.
Impact on the World
The potential impact of this investigation on the biotech industry and the world at large is significant. If it is determined that Pliant and its executives made false or misleading statements, it could lead to increased scrutiny of other biotech companies in the industry. This, in turn, could lead to a decrease in investor confidence and a slowdown in investment in the sector.
Conclusion
Pomerantz LLP is dedicated to protecting investors’ rights, and the investigation into potential securities claims against Pliant Therapeutics is a testament to this commitment. The firm encourages investors to contact Danielle Peyton if they have suffered a loss and believe they may be entitled to recover their damages. The investigation is ongoing, and more information will be provided as it becomes available.
- Pomerantz LLP is investigating potential securities claims against Pliant Therapeutics, Inc.
- The investigation concerns statements made by the Company regarding the development and commercial potential of PLN-74801.
- Individual investors who have suffered a loss may be entitled to recover their damages.
- The potential impact on the biotech industry and the world at large could be significant.
